UBS Group
RCKTW

UBS Group’s Rocket Pharmaceuticals Warrant RCKTW Stock Holding History

UBS Group’s Portfolio RCKTW Stock Details RCKTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,981
Closed -$84 – 10936
2026
Q1 		$84 Buy
+3,981
New +$80 ﹤0.01% 10142
2025
Q4 		– Sell
-1,274
Closed -$50 – 11058
2025
Q3 		$50 Buy
+1,274
New +$50 ﹤0.01% 10023
2024
Q3 		– Sell
-24
Closed -$1 – 9971
2024
Q2 		$1 Sell
24
-75
-76% -$9 ﹤0.01% 9434
2024
Q1 		$30 Buy
+99
New +$31 ﹤0.01% 8991

Other funds holding RCKTW

BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

UBS Group's RCKTW Position: Q2 2026 in Review

UBS Group sold out of Rocket Pharmaceuticals Warrant (RCKTW) in Q2 2026, closing a stake of 3,981 shares — an estimated $84 sold.

UBS Group first reported a position in RCKTW in Q1 2024 and held it in 4 quarters. The position peaked at $84 in Q1 2026. 11 funds tracked by Wall St. Rank hold RCKTW as of Q2 2026.

  • UBS Group reported no remaining Rocket Pharmaceuticals Warrant position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 3,981 Rocket Pharmaceuticals Warrant shares in Q2 2026, an estimated $84.
  • UBS Group first reported a position in Rocket Pharmaceuticals Warrant in Q1 2024 and held it in 4 quarters.
  • UBS Group's Rocket Pharmaceuticals Warrant position peaked at $84 in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Rocket Pharmaceuticals Warrant as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.